Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Novo Nordisk · Phase 2 · Completed · Enrollment 957

NCT02453711

EudraCT 2014-001540-38

ArmPopulationDoseWeeksEstimandWeight change
Sema 0.05 mgObesity or overweight0.05 mgn/rn/rn/r
Sema 0.1 mgObesity or overweight0.1 mgn/rn/rn/r
Sema 0.2 mgObesity or overweight0.2 mgn/rn/rn/r
Sema 0.3 mgObesity or overweight0.3 mgn/rn/rn/r
Sema 0.4 mgObesity or overweight0.4 mgn/rn/rn/r
Sema 0.3 mg (fast dose escalation)Obesity or overweight0.3 mgn/rn/rn/r
Sema 0.4 mg (fast dose escalation)Obesity or overweight0.4 mgn/rn/rn/r
Lira 3.0 mgObesity or overweight3.0 mgn/rn/rn/r
Placebo Sema 0.05 mgObesity or overweight0.05 mg52ITTn/r
Placebo Sema 0.1 mgObesity or overweight0.1 mg52ITTn/r
Placebo Sema 0.2 mgObesity or overweight0.2 mg52ITTn/r
Placebo Sema 0.3 mgObesity or overweight0.3 mgn/rn/rn/r
Placebo Sema 0.4 mgObesity or overweight0.4 mgn/rn/rn/r
Placebo Sema 0.3 mg (fast dose escalation)Obesity or overweight0.3 mg52ITTn/r
Placebo Sema 0.4 mg (fast dose escalation)Obesity or overweight0.4 mg52ITTn/r
Placebo Lira 3.0 mgObesity or overweight3.0 mg52ITTn/r